Former President and Chief Executive Officer · Voyager Therapeutics, Inc. (VYGR)

Steven Paul

A named executive officer of Voyager Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$7,879,739

Salary $298,291Stock awards $0

FY2017: $2,655,385

2nd of 4 named executive officers at Voyager Therapeutics by FY2018 total.

4 named officers on file for Voyager Therapeutics, FY2018

Steven Paul’s pay file — $29

  • 2 fiscal years of pay, line by line
  • VYGR’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Voyager Therapeutics’s whole pay program stands against its peers

  • Voyager Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VYGR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 23, 2019 (DEF 14A).

Free

Get Steven Paul’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Steven Paul compensation by year

Voyager Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Voyager Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018
Salary$506,900$298,291
Bonus$0$0
Stock awards$0$0
Option awards$1,860,672$7,474,994
Non-equity incentive$239,510$0
Pension and deferred compensation$0$0
All other$48,303$106,454
Total$2,655,385$7,879,739

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Voyager Therapeutics, Inc. DEF 14A filed April 23, 2019, accession 0001558370-19-003181, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Voyager Therapeutics, Inc. filed document, accession 0001558370-19-003181. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2019.

$2.7M
$7.9M
FY17
FY18
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
Option11,765—$8.33
Option58,334—$11.09
Option130,000—$11.83
Option68,750—$28.72

Per the Outstanding Equity Awards at Fiscal Year-End table in Voyager Therapeutics, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Voyager Therapeutics’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
G. Andre TurennePresident and Chief Executive Officer$8,209,845
Steven Paul · this pageFormer President and Chief Executive Officer$7,879,739
Matthew OttmerChief Operating Officer$1,848,457
Dinah SahChief Scientific Officer$1,809,745

Board service

Voyager Therapeutics board · FY2021
Director compensation in US dollars, as Voyager Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2021$44,500—$41,334$0$85,834

Each year as the company reported it in Voyager Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Voyager Therapeutics pays directors a $40,000 cash retainer. As stated in Voyager Therapeutics's FY2021 proxy.

The full Voyager Therapeutics compensation record

free company brief

This page is one person within Voyager Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Voyager Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Voyager Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Steven Paul's compensation dossier · One-time report. No refunds.